Take-at-home drug can ‘disarm' cancer
The drug, known as KCL-HO-1i, works by disarming a defence mechanism that tumours use to protect themselves. Early tests on mice found the drug even helped chemotherapy-resistant tumours to respond to treatment.
It is hoped KCL-HO-1i can be trialled on humans, with researchers suggesting it could one day be a 'valuable companion drug' to chemotherapy, helping patients to avoid more aggressive treatments.
Chemotherapy is used to treat many kinds of cancer and works by disrupting the way cancer cells grow and divide. However, it is not as effective as it should be in some patients because the body's own immune cells can act as a barrier around tumours.
These cells produce a protein called heme oxygenase-1 (HO-1), which helps shield the tumour from the immune system and block the effects of chemotherapy.
Exciting step forward
KCL-HO-1i, created at King's College London (KCL), targets this protein to make tumours more responsive to treatment.
Prof James Arnold, the head of the tumour immunology group at the university, said it discovered the cells responsible for protecting the body's immune system 'play a key role in blocking chemotherapy'.
|He said: 'By targeting the enzyme they produce using KCL-HO-1i, we were able to help beneficial immune cells and chemotherapy drugs become significantly more effective.
'In laboratory models, even chemotherapy-resistant tumours became responsive to treatment, which is a really exciting step forward.'
The drug has been designed for patients to take at home as a tablet between chemotherapy sessions.
Spin-out company
Early tests on mice, with the results published in the journal Science Translational Medicine, found the drug made breast cancer tumours more responsive to different types of chemotherapy.
Researchers are now hopeful that trials involving patients with breast cancer and other forms of the disease could begin within two years.
Prof James Spicer, a professor of experimental cancer medicine at KCL, said: 'Chemotherapy remains a key part of treatment for many patients with cancer, but too often it is not as effective or long-lasting as we might like.
'This research has identified a key reason for these limitations, and discovered a drug that we are keen to test in the clinic alongside established chemotherapy drugs.'
Miraz Rahman, a professor of medicinal chemistry at KCL, added: 'If human trials are successful, KCL-HO-1i could become a valuable companion drug to existing cancer therapies – helping more patients to benefit from the treatments that are already available and reduce the need for more aggressive cancer therapies in the future.'
The King's College London scientists have launched a spin-out company called Aethox Therapeutics.
Tanya Hollands, the research information manager at Cancer Research UK, which supported the study alongside funding from the Medical Research Council, said: 'Researchers are increasingly learning how to make better use of existing cancer treatments, whether it's using them differently or in combination with new medicines, like this work suggests.
'Using combination therapies can help bring improved treatment options to patients more quickly, safely and affordably, because some components of the treatment have already been tested and used in the clinic.
'While early stage, it's exciting to see this potential new way to disarm cancer's ability to avoid detection by the immune system with a new drug, while also boosting the effectiveness of chemotherapy, and we look forward to seeing how this work progresses.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
This drug can turn your blood into mosquito poison
Mosquitoes may have just met their match: A prescription drug already used to treat a rare genetic disease in humans can make a person's blood poisonous to insecticide-resistant, malaria-carrying mosquitoes. New research published on July 31, 2025, in Parasites & Vectors found that the same drug, nitisinone, can even kill mosquitoes that simply land on a surface sprayed with the chemical. The findings could open up new avenues to stop the spread of diseases like malaria and dengue, especially as more mosquito populations evolve to become resistant to traditional prevention methods. Whether people will willingly offer their bodies as mosquito blood bait, though, remains less clear. 'This study demonstrates that nitisinone exhibits a novel mode of action distinct from current [insecticides] by specifically targeting blood digestion processes,' the researchers write. Toxic blood Nitisinone is a pharmaceutical drug derived from a toxin naturally found in the Australian bottlebrush plant. Initially intended for use as an herbicide, the drug targets a nonessential amino acid called tyrosine, which plays an important role in producing and regulating hormones. Research in the late 20th century discovered that nitisinone was also effective in treating tyrosinemia type I and alkaptonuria, two rare genetic disorders that impair the body's ability to metabolize tyrosine. The FDA approved the drug in 2002 to treat those suffering from these conditions. But the same process that helps humans metabolize tyrosine also acts as a kind of amino acid sabotage to blood-sucking mosquitoes. Earlier this year, researchers writing in Science Translational Medicine found that mosquitoes that fed on the blood of humans taking nitisinone died within several hours of their meal. And while patients typically take nitisinone in relatively high doses, the researchers found that the toxic effect on mosquitoes occurs even when the drug is taken in substantially lower amounts. The poisoning process blocks an enzyme mosquitoes need to process proteins and amino acids in blood. Introducing nitisinone disrupts their 'bloodmeal digestion' and effectively clogs the mosquitoes' digestive system. In other words, the drug takes mosquitoes' ability to convert protein from human blood—and turns it against them. But the new findings in the Parasites & Vectors study suggest this same poisoning process could also work without having to administer nitisinone to humans. In their tests, researchers exposed several mosquito species to surfaces treated with nitisinone and four other HPPD inhibitors, both before and after the insects fed on a blood sample. According to the study, the mosquitoes absorbed nitisinone through their feet. Over the course of several hours, nitisinone had similar poisoning effects on mosquitoes as it did on those that drank the treated blood. In every case, exposure to nitisinone caused paralysis. All of the affected mosquitoes also darkened in color. While researchers are confident the process works, they still aren't exactly sure why. It remains unclear how nitisinone is absorbed through the mosquitoes' feet or why the other three similar drugs didn't produce the same deadly results. 'This project proved how important it is to think outside the box,' paper senior author and Honorary Research Fellow at LSTM Lee Haines said in a statement. A new tool to fight resistant skeeters As anyone who's tried—and failed—to mosquito-proof their yard with bug spray knows, it doesn't always work. And that's not just a matter of user error: Insecticide-resistant mosquito variants are becoming increasingly common around the world. Some studies suggest that mosquitoes capable of surviving prolonged exposure to current insecticides make up as much as 30 percent of the population. Research from the World Health Organization estimates that mosquitoes resistant to at least one insecticide have been detected in over 90 percent of countries where malaria is considered endemic. That's a troubling trend, especially considering malaria still infects an estimated 263 million people every year, nearly 600,000 of which end up dying from it. Related Mosquito Stories How to build a mosquito kill bucket What would a world without mosquitoes look like? 11 home remedies for mosquito bites to battle the itch Mosquitoes can barely see–but a male's vision perks up when they hear a female Can a bold new plan to stop mosquitoes catch on? The nitisinone findings offer an encouraging sign that effective alternatives for controlling mosquito populations may already exist. Evidence that mere exposure to surfaces treated with the drug is an effective skeeter killer suggests nitisinone could potentially be applied to nets or other bedding materials as an alternative to traditional insecticides. 'Working with a drug like nitisinone, and its versatility, bodes well for creating new products to combat mosquitoes,' Haines said. 'The fact that it effectively kills insecticide-resistant mosquitoes could be a game-changer in areas where resistance to current insecticides is causing public health interventions to fail.' Humans certainly aren't lacking in creativity when it comes to killing mosquitoes. Genetically modified mosquitoes designed only to produce male offspring have been released in certain parts of the U.S. with the hopes that they will reduce overall populations. In Hawaii, the firm Drone Amplified recently dropped dozens of biodegradable, lab grown mosquito pods over forest areas in effort to combat the area's invasive mosquito population. More recently, scientists in China released cannibal 'elephant mosquitos' that are intended to eat the larvae of their smaller cousins capable of carrying dengue. Those more extravagant solutions aren't always necessary though. In the future, households looking to keep the buzzing at bay might simply be able to rub so nitisinone on their screens. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Husband's demand for ‘me time' after ‘stressful' work day scrutinized by stay-at-home-mom sympathizers: ‘Can you buck up?'
Working six days a week in healthcare isn't exactly a picnic — but one husband's plea for 'me time' after his grueling shifts has sparked a Reddit uproar in defense of his stay-at-home wife's nonstop kid-wrangling gig. The man, a dad of three — ages nine, six and two — recently spilled his burnout woes on Reddit's AITAH [Am I The A—hole?] forum. 'I work in healthcare, so I can have pretty full-on/stressful days and can often feel very emotionally as well as physically drained when I get home from work and have been feeling increasingly burnt out recently.' After long, stressful days, he claimed he's running on empty. 'I find I can function at work to get the job done, but once I'm home, I've got nothing in the tank, which leads to having very little patience and really only being present in body only,' he wrote. His only 'me time,' he explained, is the commute home and a rare weekly run, with post-bedtime doom-scrolling and TV binges to recharge. The real kicker? He's expected to tag-team with wifey to wrestle with his little rascals as soon as he enters the ring. The man asked bluntly, 'AITAH [am I the a—hole] for wanting some me time when I get home?' Reddit users were quick to weigh in — and it wasn't a unanimous cheer squad. 'Can you get a sitter or someone to watch the kids for 1-2 days a week?' one practical soul suggested. Another dropped marriage counselor wisdom: 'The solution was for him to have 10-15 minutes decompression time when he got in from work. But once that time was up, he had to do whatever she needed him to do.' Some users, however, served a cold dose of reality. 'I'm a physician (F). My ex-wife raised our 2 kids while I did a very stressful job… So I guess you signed up for having kids? Do you want someone else to raise them? Can you buck up and realize you are all in? … You need to understand that it's a sacrifice and it won't be forever.' Others called out the dad for overlooking his wife's nonstop 24/7 grind. 'NTA [not the a—hole] for now, but leaning towards YTA [you're the a—hole]. What breaks does the stay-at-home Mom get? What adult interaction does she get? Does she have a commute to decompress? Does she get ME time?' 'You get vacation time… when is hers? Not only is she raising kids, she's managing the house, cooking, cleaning and mental load… Grow up and be a partner.' Still, some offered a middle ground. 'NTA for wanting a little me time, but you also have to think about your wife's me time too. Talk to her… maybe call a sitter, schedule her a spa day during your work hours and let her have her me time that day and have your me time the day after… You guys have to communicate and compromise.' As previously reported by The Post, today's busy parents are finding creative ways to make every second count with their kids — like millennial stay-at-home mom Sara Martinez, who went viral with the '9-minute theory,' spotlighting three key three-minute windows a day when parental presence matters most. From Upper West Side entrepreneurs hiring help to moms moving off the grid for quality time, parents are reshaping the rules on how to balance burnout and bonding — proving that sometimes, it's less about quantity and more about making moments count. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
With a new COVID variant on the rise, which US states have the most cases?
Some states are being hit harder than others this summer as a new COVID-19 strain (XGF) continues to spread. Some regions of the U.S. are still experiencing higher rates of positive COVID tests than others, though reporting has slowed down enough nationwide that the Centers for Disease Control (CDC) has begun allowing more time to pass between certain types of updates, such as those on variant prevalence. Testing, cases, hospitalizations and deaths are still being recorded on a weekly basis, however, even amid the chaos of ever-changing strains, recommendations and cuts to vaccine development funding. Here's what to know about the latest data. How many COVID cases were reported nationwide? During the week ending on Aug. 2, 8.5% of the 25,731 Americans tested were positive for COVID, according to the CDC's latest data. This was 2% increase from the week prior. During the same period, only 0.3% of cases resulted in death and 0.9% resulted in an emergency room visit, a 0.1% decrease from the week prior for both categories. More: What is an mRNA vaccine, and why is it controversial? Where are the most COVID cases being reported? See map Western and southern states, including Washington, Oregon, Idaho, California, Nevada, Arizona, New Mexico, Texas, Oklahoma, Arkansas and Louisiana, had higher percentages of positive COVID tests during the week ending Aug. 2. What is the most common COVID variant? The CDC has moved to using longer data timeframes for COVID tracking due to low reporting from states. According to the latest data for the two weeks ending June 21, variant NB.1.8.1 remained the most common, accounting for 43% of cases, followed by LP.8.1 at 31% of cases and XFG at 14%. NB.1.8.1 experienced a meteoric rise to becoming the predominant variant, accounting for 0% of cases in April and only 10% in the last week of May, up to 24% at the beginning of June and 43% by the end. XFG, a combination of variants F.7 and LP.8.1.2, is on the rise as of late, having been responsible for 0% of U.S. cases through March, 11% by early June and 14% by late June. This article originally appeared on USA TODAY: COVID variants, testing and deaths: What to know this week Solve the daily Crossword
